Advertisement

Cancer Causes & Control

, Volume 28, Issue 8, pp 857–866 | Cite as

Coffee consumption and risk of renal cell carcinoma

  • Samuel O. Antwi
  • Jeanette E. Eckel-Passow
  • Nancy D. Diehl
  • Daniel J. Serie
  • Kaitlynn M. Custer
  • Michelle L. Arnold
  • Kevin J. Wu
  • John C. Cheville
  • David D. Thiel
  • Bradley C. Leibovich
  • Alexander S. ParkerEmail author
Original paper

Abstract

Background

Studies have suggested an inverse association between coffee consumption and risk of renal cell carcinoma (RCC); however, data regarding decaffeinated coffee are limited.

Methods

We conducted a case–control study of 669 incident RCC cases and 1,001 frequency-matched controls. Participants completed identical risk factor questionnaires that solicited information about usual coffee consumption habits. The study participants were categorized as non-coffee, caffeinated coffee, decaffeinated coffee, or both caffeinated and decaffeinated coffee drinkers. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression, adjusting for multiple risk factors for RCC.

Results

Compared with no coffee consumption, we found an inverse association between caffeinated coffee consumption and RCC risk (OR 0.74; 95% CI 0.57–0.99), whereas we observed a trend toward increased risk of RCC for consumption of decaffeinated coffee (OR 1.47; 95% CI 0.98–2.19). Decaffeinated coffee consumption was associated also with increased risk of the clear cell RCC (ccRCC) subtype, particularly the aggressive form of ccRCC (OR 1.80; 95% CI 1.01–3.22).

Conclusions

Consumption of caffeinated coffee is associated with reduced risk of RCC, while decaffeinated coffee consumption is associated with an increase in risk of aggressive ccRCC. Further inquiry is warranted in large prospective studies and should include assessment of dose–response associations.

Keywords

Coffee Decaffeinated coffee Kidney cancer Renal cell carcinoma RCC Clear cell renal cell carcinoma 

Abbreviations

BMI

Body mass index

ccRCC

Clear cell renal cell carcinoma

CI

Confidence interval

OR

Odds ratio

RCC

Renal cell carcinoma

SSIGN

Stage, size, grade, and necrosis

Notes

Acknowledgments

We are indebted to the participants of the Mayo Clinic Kidney Cancer Registry, participants of Mayo Clinic Biobank, and the participants from the Department of Family and Community Medicine at Mayo Clinic, Jacksonville, FL for their invaluable contributions to the study. The authors thank Victoria L. Jackson, MLIS, ELS, for her assistance with manuscript preparation and management.

Funding

The study was supported by a grant from the State of Florida James and Esther King Biomedical Research Program.

Author contributions

SOA contributed in interpretation of data; drafting of the manuscript; final approval of the manuscript. JEE-P contributed in analysis and interpretation of data; critically revising the article; final approval of the manuscript. NDD contributed in analysis and interpretation of data; final approval of the manuscript. DJS contributed in analysis and interpretation of data; final approval of the manuscript. KMC contributed in acquisition of data; final approval of the manuscript. MLA contributed in acquisition of data; final approval of the manuscript. KJW contributed in acquisition of data; final approval of the manuscript. JCC contributed in acquisition of data; final approval of the manuscript. DDT contributed in acquisition of data; final approval of the manuscript. BCL contributed in acquisition of data; final approval of the manuscript. ASP contributed in conception and design; analysis and interpretation of data; drafting the article; final approval of the manuscript.

Compliance with ethical standards

Conflicts of interest

The authors have no conflicts of interest related to this work.

Ethical approval

The study was approved by the Mayo Clinic Institutional Review Board.

Supplementary material

10552_2017_913_MOESM1_ESM.docx (33 kb)
Supplementary material 1 (DOCX 32 kb)

References

  1. 1.
    Lipworth L et al (2011) Renal cancer paradox: higher incidence but not higher mortality among African-Americans. Eur J Cancer Prev 20(4):331–333CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    King SC et al (2014) Continued increase in incidence of renal cell carcinoma, especially in young patients and high-grade disease: United States 2001 to 2010. J Urol 191(6):1665–1670CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Sun M et al (2011) Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 59(1):135–141CrossRefPubMedGoogle Scholar
  4. 4.
    Benichou J et al (1998) Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol 148(5):424–430CrossRefPubMedGoogle Scholar
  5. 5.
    Ljungberg B et al (2011) The epidemiology of renal cell carcinoma. Eur Urol 60(4):615–621CrossRefPubMedGoogle Scholar
  6. 6.
    Svilaas A et al (2004) Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans. J Nutr 134(3):562–567PubMedGoogle Scholar
  7. 7.
    Maclure M, Willett W (1990) A case-control study of diet and risk of renal adenocarcinoma. Epidemiology 1(6):430–440CrossRefPubMedGoogle Scholar
  8. 8.
    McCredie M, Ford JM, Stewart JH (1988) Risk factors for cancer of the renal parenchyma. Int J Cancer 42(1):13–16CrossRefPubMedGoogle Scholar
  9. 9.
    Talamini R et al (1990) A case-control study of risk factor for renal cell cancer in northern Italy. Cancer Causes Control 1(2):125–131CrossRefPubMedGoogle Scholar
  10. 10.
    Benhamou S et al (1993) Risk factors for renal-cell carcinoma in a French case-control study. Int J Cancer 55(1):32–36CrossRefPubMedGoogle Scholar
  11. 11.
    Kreiger N et al (1993) Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 4(2):101–110CrossRefPubMedGoogle Scholar
  12. 12.
    Yuan JM et al (1998) Cruciferous vegetables in relation to renal cell carcinoma. Int J Cancer 77(2):211–216CrossRefPubMedGoogle Scholar
  13. 13.
    Yu MC et al (1986) Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 77(2):351–356PubMedGoogle Scholar
  14. 14.
    McLaughlin JK et al (1984) A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst 72(2):275–284PubMedGoogle Scholar
  15. 15.
    Niseteo T et al (2012) Bioactive composition and antioxidant potential of different commonly consumed coffee brews affected by their preparation technique and milk addition. Food Chem 134(4):1870–1877CrossRefPubMedGoogle Scholar
  16. 16.
    Preedy VR (2014) Processing and impact on antioxidants in beverages, 1st edn. Academic Press, San DiegoGoogle Scholar
  17. 17.
    Schapira J, Schapira K, Schapira D (1982) The book of coffee and tea: a guide to the appreciation of fine coffees, teas, and herbal beverages, 2nd edn. St. Martin’s Press, New YorkGoogle Scholar
  18. 18.
    Page BD, Charbonneau CF (1984) Headspace gas chromatographic determination of methylene chloride in decaffeinated tea and coffee, with electrolytic conductivity detection. J Assoc Off Anal Chem 67(4):757–761PubMedGoogle Scholar
  19. 19.
    Lee JE et al (2007) Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. Int J Cancer 121(10):2246–2253CrossRefPubMedGoogle Scholar
  20. 20.
    Montella M et al (2009) Coffee, decaffeinated coffee, tea intake, and risk of renal cell cancer. Nutr Cancer 61(1):76–80CrossRefPubMedGoogle Scholar
  21. 21.
    Frank I et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6):2395–2400CrossRefPubMedGoogle Scholar
  22. 22.
    Fujii Y et al (2008) External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. J Urol 180(4):1290–1295 discussion 1295-6 CrossRefPubMedGoogle Scholar
  23. 23.
    Zigeuner R et al (2010) External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 57(1):102–109CrossRefPubMedGoogle Scholar
  24. 24.
    Olson JE et al (2013) The Mayo Clinic Biobank: a building block for individualized medicine. Mayo Clin Proc 88(9):952–962CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Leibovich BC et al (2010) Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. Urology 183(4):1309–1316CrossRefGoogle Scholar
  26. 26.
    Arnlov J, Vessby B, Riserus U (2004) Coffee consumption and insulin sensitivity. JAMA 291(10):1199–1201CrossRefPubMedGoogle Scholar
  27. 27.
    Van Dam RM, Hu FB (2005) Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 294(1):97–104CrossRefPubMedGoogle Scholar
  28. 28.
    Wu T et al (2005) Caffeinated coffee, decaffeinated coffee, and caffeine in relation to plasma C-peptide levels, a marker of insulin secretion, in U.S. women. Diabetes Care 28(6):1390–1396CrossRefPubMedGoogle Scholar
  29. 29.
    Leon-Carmona JR, Galano A (2011) Is caffeine a good scavenger of oxygenated free radicals? J Phys Chem B 115(15):4538–4546CrossRefPubMedGoogle Scholar
  30. 30.
    Anissi J et al (2014) A comparative study of the antioxidant scavenging activity of green tea, black tea and coffee extracts: a kinetic approach. Food Chem 150:438–447CrossRefPubMedGoogle Scholar
  31. 31.
    Arnaud M (1993) Metabolism of caffeine and other components of coffee. In: Garattini S (ed) caffeine, coffee and health. Raven Press, New York, pp 43–95Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Samuel O. Antwi
    • 1
  • Jeanette E. Eckel-Passow
    • 2
  • Nancy D. Diehl
    • 1
  • Daniel J. Serie
    • 1
  • Kaitlynn M. Custer
    • 1
  • Michelle L. Arnold
    • 1
  • Kevin J. Wu
    • 3
  • John C. Cheville
    • 3
  • David D. Thiel
    • 4
  • Bradley C. Leibovich
    • 5
  • Alexander S. Parker
    • 1
    Email author
  1. 1.Department of Health Sciences ResearchMayo ClinicJacksonvilleUSA
  2. 2.Department of Health Sciences ResearchMayo ClinicRochesterUSA
  3. 3.Department of Laboratory Medicine and PathologyMayo ClinicJacksonvilleUSA
  4. 4.Department of UrologyMayo ClinicJacksonvilleUSA
  5. 5.Department of UrologyMayo ClinicRochesterUSA

Personalised recommendations